Over 1.7 million people worldwide suffer from blindness caused by retinitis pigmentosa (RP), a group of hereditary disorders that cause progressive loss of first rod and then cone photoreceptors. Mutations in rhodopsin (Rho) account for close to 30% of all autosomal dominant (ADRP) cases, and the most common mutation in North America, Rho P23H , involves a single amino acid change at position 23 at the N-terminal region of the protein. 1, 2 The molecular/cellular mechanism leading to rod cell death in Rho P23H -linked RP is still subject to debate. Current models include misregulation of stress pathways, involving endoplasmic reticulum-associated degradation (ERAD) and unfolded protein response (UPR), [3] [4] [5] [6] [7] or the disruption of membrane disks in the outer segment (see Figure 1 for current models). [8] [9] [10] [11] [12] Studies in transfected cells and transgenic animals show Rho P23H to be a misfolded protein that forms aberrant oligomers and aggregates, and is largely found within the cell body. 3, [13] [14] [15] Notwithstanding the many unanswered questions on the etiology of the disease, it is this accumulation of abnormal protein aggregates that is thought to eventually lead to photoreceptor cell death. [3] [4] [5] [6] 8, 10 Currently, there are no effective treatments for RP. Translational approaches focus on 1) removing the mutant protein by suppressing expression or enhancing degradation, 2) promoting cell survival by delivering neurotrophic factors, or 3) suppressing cell death. 16, 17 Several models that recapitulate aspects of RhoP23H pathology are used in these studies. 11, 15, [18] [19] [20] [21] Animal models (frog, rat, mouse, pig) offer platforms that are photoreceptorcell-based and thus more relevant from a pathophysiological standpoint. In these systems, however, the large-scale approaches necessary Figure 1 . In healthy vertebrate photoreceptor cells (diagrammed on the left), wild type rhodopsin (WT RHO) is correctly folded and delivered to the membrane disks in the rod outer segment (OS). Very little, if any, rhodopsin is detected in the inner segment. Instead, improperly folded mutant rhodopsins (particularly Class II mutants 4 ) are prone to forming oligomers and aggregates that are found largely in the cytoplasm but also in small amounts within the rod OS (diagrammed on the right). The pathogenic mechanism by which Rho P23H leads to cell death is still the subject of debate [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Experimental evidence suggests one of two possible sites of action: 1) within the cell body, by impairing the protein quality-control systems (ERAD and UPR), or 2) in the rod OS, by disrupting some critical function of the disks or the rod's structural integrity. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] ERAD, endoplasmic reticulum-associated degradation; UPR, unfolded protein response for genetic or pharmacological screens are either not feasible (frog, pig) or prohibitively expensive (mouse, rat). On the contrary, cell culture is ideally suited for large-scale studies. Nevertheless, heterologous cell types lack critical features of photoreceptor cells, including specialized cellular structures and the machinery to house and process enormous quantities of membranes (protein and lipids). For these reasons and the resulting Rho-induced toxicity, the cell culture model is significantly limited.
Invertebrate models have been extensively used in the study of disease mechanisms thanks to their low cost, robust conservation of key physiological processes, and availability of sophisticated tools for detailed analyses as well as large-scale approaches (for instance, in the study of human neurodegenerative diseases). [22] [23] [24] [25] Among them, Drosophila presents an extremely well studied visual system whose developmental origin relies on many of the same molecular factors as the vertebrate eye. 26 Yet, the fruit fly has been rarely utilized in the analysis of mammalian proteins linked to vision loss, largely because of the structural and functional distinctiveness of compound and camera eyes.
Is the Drosophila Model Relevant to the Metabolism of Mammalian Opsins?
There are striking differences between photoreceptor cells of flies and vertebrates, particularly in visual transduction and cellular structure (see comparison in Figure 2) . 27 These differences obviously reflect a long history of independent evolution of light perception and vision in vertebrates versus invertebrates. For this reason, Drosophila has not been exploited as a host organism in the study of mammalian opsins. However, this should be reconsidered in light of new findings on the morphogenesis of the phototransduction compartments and the maturation, transport and degradation of opsins in flies and mouse photoreceptors.
Drosophila photoreceptor cells (aka R-cells) can produce bovine or murine Rhodopsin as stable proteins that can traffic correctly to the rhabdomere (Fig. 3A) . 28 The bovine opsin has also been shown to be functional when presented with the appropriate G protein, G t Transducin. 28 Moreover, a number of studies have uncovered similarities in the processing and transport of opsins. Transport of both the fly rhodopsin Rh1 and mammalian Rho involve the exocyst complex, Rab11 and myosins (V in flies and VIIA in mouse). [29] [30] [31] [32] [33] In regards to Rhodopsin degradation, the ERAD effector valosin-containing protein (VCP) acts as a molecular chaperone for both fly and mammalian proteins. 34, 35 Additional evidence comes from the associations of factors required in R-cells with human eye diseases. Mutations in Crumbs homolog 1 (the vertebrate homologue of Crumbs, a critical cell polarity factor that also facilitates rhodopsin trafficking in fly photoreceptors) are associated with retinal degeneration in fly and mouse, and retinitis pigmentosa in humans. 36, 37 Multiple cases of Usher syndrome have been mapped to the region of the DENN/MADD domain containing 4A (DENND4A) locus, the human homologue of fly Crag, which plays an integral role in the trafficking of Rh1. 38, 39 Lastly, prominin, a factor recently implicated in the elaboration of phototransduction compartments in both rhabdomeric and ciliary photoreceptors, is linked to retinitis pigmentosa and Stargardt disease. [40] [41] [42] As many genes involved in the processing of Rh1 and Rho have not been identified, additional factors in common between vertebrates and invertebrates will certainly emerge from further studies.
In addition, nearly all Rho-processing components have corresponding fly homologues that may also be active in processing of Rh1, or be recruited for production of Rho in R-cells. Interestingly, maturation of the mammalian protein does not require the Rh1-specific, endoplasmic reticulum (ER)-based chaperone NinaA (a cyclophillin), 28, 43 but does appear to depend on Nuf, a fly homologue of Rab11 family-interacting protein 3 (Fig. 3B) , a critical factor for the transport of Rho from the transGolgi network in mouse rods. 30 Further analysis of evolutionarily conserved and fly-specific To explore this question, we expressed mouse mutant Rho P23H (mRho P23H ) in R-cells. In contrast to wild type mRho, the mutant opsin does not localize to the rhabdomere, displays lower protein stability, oligomerizes and forms abnormal intracellular foci ( Figures 3C and  3D ). In essence, mRho P23H shows a pattern of phenotypic abnormalities in R-cells strikingly similar to the aberrant behavior of this protein in vertebrate photoreceptors.
Importantly, we can detect alterations in the localization and/or stability of this mutant rhodopsin by measuring changes in GFP-fluorescence. This is achieved by using Rho-eGFP fusions and detecting fluorescence in adult eyes or dissected retinas (live or fixed tissue) ( Figures 3F-I and 3A-C, respectively) . Hence, modifiers that increase stability, folding, and rhabdomeric localization of Rho P23H -eGFP will lead to increased fluorescence, whereas modifiers that decrease rhabdomeric localization and/or protein stability will lead to decreased fluorescence. Thus, a fly model of mammalian Rho P23H may address the present lack of photoreceptor-based models suitable for largescale applications.
In conclusion, a screening platform for genetic and pharmacological modifiers of misfolded mammalian rhodopsin is now available in the powerful genetic Drosophila model. 44 This provides an innovative, in vivo approach for the discovery of novel drugs or targets.
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